Immunometabolic interactions in individuals with down syndrome across childhood, adolescence and adulthood in relation to their siblings - Report - MDSpire
Advertisement
Immunometabolic interactions in individuals with down syndrome across childhood, adolescence and adulthood in relation to their siblings
Clinical Report: Immunometabolic Relationships in Individuals with Down Syndrome
Overview
This study evaluates immunometabolic interactions in individuals with Down syndrome (DS) across different age groups, revealing significant differences in inflammatory and metabolic parameters compared to their siblings. Key findings include higher obesity rates and altered cytokine levels in the DS group.
Background
Down syndrome is the most common chromosomal disorder, associated with immune dysregulation and metabolic disorders, including increased cardiovascular disease risk.
Data Highlights
Parameter
DS Group (n=42)
Control Group (n=21)
p-value
Ponderal Mass Index (TMI)
Higher
Lower
0.04
Non-HDL
Higher
Lower
0.02
apoB
Higher
Lower
0.04
IL-10
Lower
Higher
0.006
IL-13
Lower
Higher
<0.01
IL-22
Lower
Higher
0.002
Key Findings
Higher obesity rates in the DS group ≤ 18 years (p=0.04).
Increased levels of non-HDL and apoB in the DS group (p=0.02 and p=0.04, respectively).
Significantly lower levels of IL-10, IL-13, and IL-22 in the DS group (p=0.006, p<0.01, p=0.002).
High diagnostic utility of apolipoprotein A (AUC = 0.818).
IL-5 showed high diagnostic utility among cytokines (AUC = 0.814).
Clinical Implications
The findings highlight the need for targeted monitoring of obesity and metabolic parameters in individuals with Down syndrome. Clinicians should consider the altered cytokine profiles when evaluating the health of patients with DS.
Conclusion
This study indicates significant immunometabolic differences in individuals with Down syndrome compared to their siblings.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
